VTX958 for Crohn's Disease (Harmony-CD Trial)

"The study is only open to participants aged 18 through 75. For those younger or older, 67 trials are available for under-18's and 197 exist for seniors over 65 years old."

"An examination of clinicaltrials.gov demonstrates that this research initiative is currently looking for participants to join the trial, which was originally made public on December 22nd 2022 and updated most recently on January 17th 2023."

"Though the efficacy of VTX958 Dose A has yet to be established, there is some data confirming its safety. Thus, our team at Power has assigned it a score of 2 out of 3 on their scale."

"Affirmative. Clinicaltrials.gov's records denote that this experiment, which was initially posted on December 22nd 2022, is still actively recruiting participants. This research venture requires the enrolment of 132 volunteers at one medical site."

"This research project is enrolling 132 persons with Crohn's disease in the age range of 18-75 years. Qualified candidates must meet certain standards: gender, consent procurement capacity, medical documentation confirming diagnosis for at least 3 months before Day 1, and exhibit moderately to severely active symptoms."

"This trial's primary objective, which will be evaluated between screening and Week 12, is the proportion of patients achieving endoscopic response by this time. Secondary outcomes for evaluation include: Proportion of participants achieving clinical remission at Week 12 (as defined by a CDAI score < 150), Proportion of participants achieving patient-reported outcome 2 (PRO2) remission at Week 12 (defined as an unweighted CDAI component with daily AP score ≤ 1 and average stool frequency score ≤ 3), and Proportion of participants attaining clinical response at Week 12 (defined as ≥ 100 points reduction from baseline in their CDAI"